SF-3636-item short form survey instrument
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
Eligible Medicare patients may now explore access through the Medicare GLP-1 Bridge Program for Wegovy or Zepbound
Talk with your doctor about which GLP-1 may be best for you
Compounded semaglutide: Contains the same active ingredient as both Ozempic and Wegovy, bypassing some of the brand-name coverage issues
Gastrointestinal Side Effects GLP-1 agonists often cause gastrointestinal side effects, such as nausea, vomiting, and diarrhea, especially when first starting the medication
